Adagene reports two collaboration milestones with Third Arc Bio and Exelixis
Adagene disclosed a lead candidate selection under its expanded Third Arc Bio deal and a $2.0 million preclinical milestone payment from Exelixis tied to its SAFEbody platform.
SEC filing (2)